OxFORD Asset Management LLP acquired a new stake in shares of Exact Sciences Corporation (NASDAQ:EXAS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 165,287 shares of the medical research company’s stock, valued at approximately $5,846,000. OxFORD Asset Management LLP owned about 0.14% of Exact Sciences Corporation at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in EXAS. Fortaleza Asset Management Inc. purchased a new stake in shares of Exact Sciences Corporation during the second quarter valued at $106,000. Northwestern Mutual Wealth Management Co. boosted its position in shares of Exact Sciences Corporation by 17.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after buying an additional 600 shares during the last quarter. Financial Architects Inc boosted its position in shares of Exact Sciences Corporation by 90.0% during the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock valued at $152,000 after buying an additional 2,035 shares during the last quarter. Johnson Financial Group Inc. boosted its position in shares of Exact Sciences Corporation by 25.9% during the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock valued at $172,000 after buying an additional 1,000 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Exact Sciences Corporation by 66.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,052 shares of the medical research company’s stock valued at $179,000 after buying an additional 2,013 shares during the last quarter. 85.22% of the stock is currently owned by institutional investors.

Several equities research analysts recently commented on EXAS shares. Craig Hallum increased their price objective on Exact Sciences Corporation from $35.00 to $41.00 in a research report on Friday, July 7th. Benchmark Co. increased their price objective on Exact Sciences Corporation from $34.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, May 31st. Roth Capital reaffirmed a “buy” rating and set a $40.00 price objective (up from $33.00) on shares of Exact Sciences Corporation in a research report on Thursday, June 1st. Canaccord Genuity increased their price objective on Exact Sciences Corporation from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, May 31st. Finally, Jefferies Group LLC set a $35.00 target price on Exact Sciences Corporation and gave the company a “buy” rating in a report on Thursday, June 1st. Five analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $42.11.

In other news, CFO Jeffrey Thomas Elliott sold 5,846 shares of the company’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $39.41, for a total value of $230,390.86. Following the sale, the chief financial officer now owns 19,861 shares in the company, valued at $782,722.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas D. Carey bought 2,500 shares of the stock in a transaction dated Thursday, August 17th. The stock was bought at an average price of $37.71 per share, for a total transaction of $94,275.00. Following the purchase, the director now directly owns 60,858 shares of the company’s stock, valued at $2,294,955.18. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 129,291 shares of company stock worth $5,288,181. Company insiders own 4.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: “OxFORD Asset Management LLP Acquires New Stake in Exact Sciences Corporation (EXAS)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/28/oxford-asset-management-llp-acquires-new-stake-in-exact-sciences-corporation-exas.html.

Exact Sciences Corporation (EXAS) opened at 47.29 on Thursday. The stock has a 50 day moving average price of $40.21 and a 200 day moving average price of $32.94. The company’s market cap is $5.63 billion. Exact Sciences Corporation has a 1-year low of $13.05 and a 1-year high of $47.48.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.10. The business had revenue of $57.65 million for the quarter, compared to the consensus estimate of $47.73 million. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. On average, equities research analysts anticipate that Exact Sciences Corporation will post ($1.18) EPS for the current fiscal year.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.